Showing results (1641-1650 of 10,079) with videos related to
Sort By:
Pageof 1,008
Current Pharmaceutical Design|August 12, 2017
Antiepileptic Treatments in Developing CountriesJeremy Jost, Athanase Millogo, Pierre-Marie PreuxCurrent Pharmaceutical Design|August 12, 2017
Imaging Biomarkers of Anti-Epileptic Drug Action: Insights from Magnetic Resonance ImagingLorenzo Caciagli, Fenglai Xiao, Britta Wandschneider, et al.Current Pharmaceutical Design|July 26, 2017
Anthocyanins: Multi-Target Agents for Prevention and Therapy of Chronic DiseasesSwathi Putta, Nagendra S Yarla, Ilaria Peluso, et al.Current Pharmaceutical Design|August 19, 2017
Genetic Variants of PEAR1 are Associated with Platelet Function and Antiplatelet Drug Efficacy: A Systematic Review and Meta-AnalysisQian Xiang, Shuang Zhou, Joshua P Lewis, et al.Current Pharmaceutical Design|July 12, 2016
Natalizumab Modifies Catecholamines Levels Present in Patients with Relapsing- Remitting Multiple SclerosisBegona M Escribano, Macarena Aguilar-Luque, Carmen Bahamonde, et al.Current Pharmaceutical Design|July 12, 2016
Lipids, Statins and Heart Failure: An UpdateNiki Katsiki, Michael Doumas, Dimitri P MikhailidisCurrent Pharmaceutical Design|August 30, 2017
The Effect of Physical Exercise on Neurogenesis Factor Production in Glial CellsJorge M Moreno-Collazos, Eva S OrtiCurrent Pharmaceutical Design|July 28, 2017
Neuroprotection in Hypoxic-Ischemic Brain Injury Targeting Glial CellsMaria Ines Herrera, Sofia Mucci, George E Barreto, et al.Current Pharmaceutical Design|August 8, 2017
The Therapeutical Effect of Chinese Medicine for the Treatment of Atherosclerotic Coronary Heart DiseaseJian Zhang, Hui Meng, Yi Zhang, et al.Current Pharmaceutical Design|May 12, 2016
How the Protein Architecture of RNases III Influences their Substrate Specificity?Guillermin Agüero-Chapin, Gisselle Pérez-Machado, Juan Collí Mull, et al.Pageof 1,008